文献速递膀胱癌与上尿路尿路上皮癌

18F-FDG PET/CT对上尿路尿路上皮癌淋巴结分期的诊断价值

Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2019-10-05

本研究回顾性纳入117例上尿路尿路上皮癌(UTUC)患者,其中62例接受淋巴结清扫(LND),评估FDG-PET/CT对淋巴结转移(LNM)的诊断价值。结果显示FDG-PET/CT诊断LNM的敏感度为82%(95%CI 57-96),特异度为84%(95%CI 71-94);PET/CT淋巴结阳性患者无复发生存(RFS)显著更差(p=0.03)。

要点

  • FDG-PET/CT诊断UTUC淋巴结转移敏感度82%、特异度84%。
  • PET/CT示淋巴结阳性与更差的无复发生存相关(p=0.03)。
  • 癌特异生存(p=0.11)和总生存(p=0.5)在两组间无显著差异。

核心结论

  • FDG-PET/CT对UTUC淋巴结转移检测的敏感度为82%,特异度为84%。
  • FDG-PET/CT上可疑淋巴结的存在与更差的无复发生存相关。

研究设计与样本

  • 回顾性多中心研究,2007至2017年间8个中心共152例UTUC患者接受FDG-PET/CT后手术,排除新辅助化疗者,最终纳入117例,其中62例接受淋巴结清扫。

主要发现

  • 17例患者经组织病理学评估确认淋巴结转移。
  • FDG-PET/CT诊断淋巴结转移的敏感度为82%(95%CI 57-96),特异度为84%(95%CI 71-94)。
  • PET/CT淋巴结阳性患者无复发生存显著差于阴性患者(p=0.03)。
  • 癌特异生存(p=0.11)和总生存(p=0.5)在两组间相似。

关键数值与推荐

  • FDG-PET/CT诊断淋巴结转移的敏感度为82%(95%CI 57-96),特异度为84%(95%CI 71-94)。

临床怎么用

  • FDG-PET/CT可用于UTUC术前淋巴结分期评估,辅助识别淋巴结转移风险。
  • PET/CT显示可疑淋巴结提示复发风险较高,可能影响术后随访策略。

局限性

  • 回顾性研究设计。
  • 样本量有限。
  • 结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Presence of lymph node metastases (LNM) is an important prognostic factor for cancer-specific survival (CSS) in patients with upper tract urothelial carcinoma (UTUC). In various neoplasms, 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) is an established modality for preoperative lymph node (LN) staging. In UTUC, the diagnostic value of FDG-PET/CT for LN staging is unknown. OBJECTIVE: To determine the diagnostic value of FDG-PET/CT for LN staging in patients with UTUC. DESIGN, SETTING, AND PARTICIPANTS: Data of 152 patients with UTUC who underwent FDG-PET/CT followed by surgical treatment in eight centers between 2007 and 2017 were retrospectively collected. Patients receiving neoadjuvant chemotherapy were excluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: FDG-PET/CT results were compared with histopathology after lymph node dissection (LND). Recurrence-free survival (RFS), CSS, and overall survival (OS) were analyzed using Kaplan-Meier estimates, and compared for patients with and without suspicious LNs on FDG-PET/CT. RESULTS AND LIMITATIONS: We included 117 patients, of whom 62 underwent LND. Seventeen patients had LNM at histopathological evaluation. Sensitivity and specificity of FDG-PET/CT for diagnosis of LNM were 82% (95% confidence interval [CI]: 57-96) and 84% (95% CI: 71-94), respectively. RFS was significantly worse in patients with LN-positive FDG-PET/CT than in those with LN-negative FDG-PET/CT (p=0.03). CSS (p=0.11) and OS (p=0.5) were similar between groups. This study is limited by its retrospective design and by its sample size. Our results warrant further validation. CONCLUSIONS: FDG-PET/CT has 82% sensitivity and 84% specificity for the detection of LNM in patients with UTUC. Presence of suspicious LNs on FDG-PET/CT is associated with worse RFS. PATIENT SUMMARY: In patients with upper tract urothelial cancer, positron emission tomography with computed tomography (PET/CT) scans can detect lymph node metastases with noteworthy accuracy. Presence of suspicious lymph nodes on 18F-fluorodeoxyglucose PET/CT is associated with worse recurrence-free survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Voskuilen CS, Schweitzer D, Jensen JB, et al. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2019. PMID: 31591037. doi:10.1016/j.euo.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。